Exon-Skipping ASOs for SMA: Nusinersen Leads the Way in 2026
Spinal muscular atrophy weakens muscles severely. It affects motor neurons early in life. SMN1 gene mutations cause the disease. SMN2 gene partially compensates. However, SMN2 skips exon 7 in most transcripts. This produces unstable protein. Therefore, functional SMN levels stay low.
Antisense oligonucleotides (ASOs) change this. They block skipping. Nusinersen (Spinraza) binds an intronic silencer. It promotes exon 7 inclusion. As a result, full-length SMN protein increases. Biogen developed this therapy. FDA approved it in 2016. It treats all SMA types.
Nusinersen delivers via intrathecal injection. It reaches the central nervous system directly. Patients receive loading doses first. Maintenance follows every four months. Clinical trials showed strong benefits. Infants gained motor milestones. Older children improved strength and function. Survival rates rose dramatically.
The therapy slows progression effectively. It halts decline in many cases. Early treatment yields best results. Presymptomatic infants often develop normally. Long-term data from 2026 confirms safety. Side effects remain manageable. Lumbar punctures cause temporary discomfort.
Researchers explore improvements. New ASOs like BIIB115 test modified backbones. They aim for longer dosing intervals. Once-yearly administration could ease burden. Prenatal delivery shows promise in models. Intra-amniotic injection boosts outcomes further.
Challenges persist. Access remains limited in some regions. Cost stays high. Repeat injections require commitment. Yet nusinersen transformed SMA care. It proves splice modulation works. Other ASOs build on this success.
In short, exon-skipping ASOs revolutionized SMA treatment. Nusinersen sets the standard. Patients gain hope and function. The field advances steadily. Future versions promise even better results. SMA no longer means inevitable decline.